Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Impact of atopic dermatitis on education and career choices: the Scars of Life international study.

The Journal of investigative dermatology·2026
Same author

The Long-Term Impact of Childhood and Adolescent Atopic Dermatitis on Physical and Psychosocial Well-Being: Scars of Life project.

Clinical and experimental dermatology·2026
Same author

More than a symptom: itch as an independent clinical contributor in atopic dermatitis - a global-scale study on 15,223 patients.

The British journal of dermatology·2026
Same author

The role of JAK3 and TEC family kinases in vitiligo pathogenesis.

Frontiers in immunology·2026
Same author

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

JAMA dermatology·2026

Related Experiment Video

Updated: May 30, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Biologics in atopic dermatitis.

Alain Taïeb1, Julien Seneschal, M Djavad Mossalayi

  • 1Department of Dermatology and Pediatric Dermatology, Inserm U 1035, University Bordeaux Segalen, France. alain.taieb@chu-bordeaux.fr

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|August 5, 2011
PubMed
Summary
This summary is machine-generated.

New biologics are needed for severe atopic dermatitis (AD). Targeting early immune responses and restoring skin barrier function are key to developing effective treatments for this chronic inflammatory skin disorder.

Related Experiment Videos

Last Updated: May 30, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Area of Science:

  • Immunodermatology
  • Molecular biology
  • Dermatology

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition.
  • Recalcitrant, autoinflammatory AD, particularly in adults, requires novel biologic therapies.
  • Varied patient responses to existing treatments highlight the need for targeted approaches.

Purpose of the Study:

  • To identify novel therapeutic targets for recalcitrant atopic dermatitis.
  • To explore strategies for developing biologics that address early immune dysregulation in AD.
  • To investigate methods for restoring epidermal homeostasis in AD patients.

Main Methods:

  • Review of current literature on atopic dermatitis pathogenesis and treatment.
  • Analysis of immune responses involved in AD, including B-cell and T-cell activation.
  • Exploration of tissue-specific factors and regulatory mechanisms in skin inflammation.

Main Results:

  • Heterogeneity in patient responses suggests diverse immune pathways in AD.
  • Targeting early allergen-specific B- and T-cell clones presents a promising therapeutic avenue.
  • Restoring epidermal barrier function is crucial alongside immune modulation.

Conclusions:

  • Developing effective biologics for severe AD necessitates targeting early immune responses.
  • Understanding and mitigating pruritogenic inflammation is essential for symptom relief.
  • Interfering with disease amplification loops by addressing aberrant regulatory mechanisms is critical for long-term disease control.